Stiff person's syndrome neurodiagnostic study was
Post# of 154782
(Total Views: 564)
Posted On: 12/19/2022 4:10:16 PM
Re: chazzledazzle #131386
Stiff person's syndrome neurodiagnostic study was not supportive of diagnosis. Good for the patient!
Speaking of SPS, with Celine Dion recent diagnosis, a different colleague was on the local news speaking about it. My neuromuscular neurology colleagues are doing some work for a few different autoimmune neuromuscular disease (there are so many of them!), like myasthenia gravis, using CAR-T against BCMA:
https://myastheniagravisnews.com/news/car-t-c...-symptoms/
Another study I reviewed is looking to use IVIG for small fiber neuropathy with certain known auto-antibodies. Interesting that IVIG has been shown to expand T-Regs.
This month I reviewed another study reviewing a drug (anti-CD38) to knock out B-cells producing antibodies involved in an autoimmune nephropathy.
Autoimmunity is a huge problem. I believe that engineered T-Regs can be helpful. Lots of money being thrown at CAR-TRegs for autoimmune diseases.
A study in the news from my alma mater shows why T-Regs become so problematic when in the cancer microenvironment:
https://www.science.org/doi/10.1126/sciadv.abo4116
Again, one wants to ramp up TRegs (which ramp down TEffectors and B-cell lineages producing auto-antibodies) for autoimmunity or GVHD, and want to tamp down / limit T-Reg migration to tumors (TRegs help tumors thrive and fight off the immune system there).
Can leronlimab really treat both types of disease, modulating TReg numbers and migration up or down as needed? Hopefully we get off the FDA's $#!+ list, find some $/partners, and can find out.
Speaking of SPS, with Celine Dion recent diagnosis, a different colleague was on the local news speaking about it. My neuromuscular neurology colleagues are doing some work for a few different autoimmune neuromuscular disease (there are so many of them!), like myasthenia gravis, using CAR-T against BCMA:
https://myastheniagravisnews.com/news/car-t-c...-symptoms/
Another study I reviewed is looking to use IVIG for small fiber neuropathy with certain known auto-antibodies. Interesting that IVIG has been shown to expand T-Regs.
This month I reviewed another study reviewing a drug (anti-CD38) to knock out B-cells producing antibodies involved in an autoimmune nephropathy.
Autoimmunity is a huge problem. I believe that engineered T-Regs can be helpful. Lots of money being thrown at CAR-TRegs for autoimmune diseases.
A study in the news from my alma mater shows why T-Regs become so problematic when in the cancer microenvironment:
https://www.science.org/doi/10.1126/sciadv.abo4116
Again, one wants to ramp up TRegs (which ramp down TEffectors and B-cell lineages producing auto-antibodies) for autoimmunity or GVHD, and want to tamp down / limit T-Reg migration to tumors (TRegs help tumors thrive and fight off the immune system there).
Can leronlimab really treat both types of disease, modulating TReg numbers and migration up or down as needed? Hopefully we get off the FDA's $#!+ list, find some $/partners, and can find out.
(5)
(0)